Phase II clinical trial of celecoxib (or nsaid) for prevention of sporadic colorectal adenomas
Ended Definitive Contract Awarded Last action
- Contract number
- 00261199903D261995015
- Awardee
-
Preventive Medicine Institute UEI MKMCB9BPZKX8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,405,823
Award facts
- Contract value 19% obligated
-
- $36,366,260.00 Current, with exercised options
- $38,582,232.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers
- Pricing
- Cost No Fee
- Place of performance
- New York, NY 10065, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,755,829 | |
| Novation Agreement | -$153,320 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $504,972 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $711,000 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,000,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $630,000 | |
| Funding Only Action | $615,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $500,000 | |
| Supplemental Agreement for work within scope | $1,941,000 | |
| Supplemental Agreement for work within scope | $1,919,000 | |
| Supplemental Agreement for work within scope | $220,000 | |
| Original award | $1,274,000 |
Show all 20
About this award
This is a definitive contract awarded by the National Cancer Institute, a civilian agency, to the Preventive Medicine Institute for a Phase II clinical trial of celecoxib (or NSAID) for the prevention of sporadic colorectal adenomas. The contract has a ceiling value of $38,582,232.00 and a completion date of March 30, 2010. It is a cost-no-fee contract and was not set aside for a specific type of business. The contract provides funding for clinical research to evaluate the effectiveness of celecoxib or another non-steroidal anti-inflammatory drug (NSAID) in preventing the development of precancerous polyps in the colon, which could help reduce the incidence of colorectal cancer.
Quick answers
Who was awarded contract 00261199903D261995015?
00261199903D261995015 was awarded to Preventive Medicine Institute by National Cancer Institute (National Institutes of Health) on March 15, 1999.
How much is contract 00261199903D261995015 worth?
The government has obligated $7,405,823 on 00261199903D261995015. Its current value, with exercised options, is $36,366,260. Its potential value, with all options, is $38,582,232.
Was contract 00261199903D261995015 competed?
The extent of competition for 00261199903D261995015 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award